Botulinum toxin A - Ipsen

Drug Profile

Botulinum toxin A - Ipsen

Alternative Names: AbobotulinumtoxinA; Azzalure; BoNT-A; BTX-A-HAC NG; Dysport; Dysport NG; Dysport RU; Dysport Solution; Dysport® Next Generation; Reloxin

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Health Protection Agency Porton Down; Ipsen Limited
  • Developer Biosintetica; Galderma; Ipsen Limited; Medicis Pharmaceutical Corporation; Valeant Pharmaceuticals International
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Facial-wrinkles; Fissure in ano; Glabellar lines; Hyperhidrosis; Muscle spasticity; Neurogenic bladder; Spasm; Torticollis
  • Phase III Overactive bladder; Urinary incontinence
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Pain

Most Recent Events

  • 15 Mar 2018 Health Canada approves a label update for botulinum toxin A in Muscle spasticity (in adults with lower limb spasticity)
  • 09 Jan 2018 Registered for Muscle spasticity (In adolescents, In children) in Canada (IM)
  • 09 Jan 2018 Updated efficacy and adverse events data from a phase III trial in Muscle spasticity released by Ipsen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top